Arrowhead Secures Over $800M to Advance Gene-Silencing Drug Pipeline

PASADENA, CA – January 08, 2026 – Arrowhead Pharmaceuticals has successfully priced a massive, upsized capital raise expected to net the company more than $796 million, providing a substantial war chest to advance its pioneering pipeline of gene-silencing therapies. The move, announced Tuesday, was met with strong investor demand and signals significant confidence in the biotechnology firm's strategy and its revolutionary RNA interference (RNAi) platform.

The complex financial maneuver involves two concurrent public offerings: $625 million in 0.00% convertible senior notes due in 2032 and a separate offering of common stock and pre-funded warrants expected to gross approximately $200 million. The company's ability to increase the size of the note offering from an initially planned $500 million underscores robust interest from the financial community, a notable feat in a biotech market that has been navigating headwinds.

A Sophisticated Funding Strategy

In a display of strategic financial engineering, Arrowhead has structured the deal to maximize capital infusion while actively managing potential shareholder dilution. The centerpiece is the $625 million offering of convertible senior notes, which are particularly attractive for the company as they carry a 0.00% interest rate, thus avoiding any impact on near-term cash flow from interest payments.

These notes will have an initial conversion price of approximately $87.07 per share, a 35% premium over the public offering price of its common stock at $64.50. This premium means that shareholders are protected from dilution unless the company's stock price appreciates significantly, aligning the interests of noteholders with long-term stockholders.

To further mitigate the dilutive impact of a potential conversion, Arrowhead simultaneously entered into privately negotiated capped call transactions. These derivative agreements are designed to effectively increase the conversion price of the notes to approximately $119.33 per share—a remarkable 85% premium over the stock offering price. This structure generally reduces the number of shares the company would need to issue if the notes are converted, protecting existing shareholders from dilution up to that cap price. This multi-pronged approach demonstrates a sophisticated understanding of capital markets, balancing the immediate need for funds with long-term value creation.

The dual offering was managed by a syndicate of top-tier investment banks, with J.P. Morgan and Jefferies acting as joint book-running managers, adding a layer of institutional validation to the transaction.

Fueling a Revolution in Medicine

The nearly $800 million in net proceeds is earmarked for accelerating Arrowhead's ambitious mission to treat intractable diseases by silencing the genes that cause them. The company, which recently transitioned to a commercial-stage entity with the 2025 launch of REDEMPLO® for a rare genetic disorder, is now powerfully positioned to fund its extensive and diverse pipeline.

A significant portion of the capital is expected to support the company's late-stage cardiovascular programs. These include plozasiran, a Phase 3 candidate for severe hypertriglyceridemia, and zodasiran, also in Phase 3 trials for mixed dyslipidemia. Positive results from these programs could unlock blockbuster markets and establish Arrowhead as a major player in cardiovascular medicine. The new funding ensures these costly late-stage trials can proceed without financial constraints.

Beyond its cardiovascular franchise, the capital will fuel innovation across Arrowhead's proprietary TRiM™ platform, which enables the delivery of RNAi therapies to a variety of tissues. This includes advancing programs into new, challenging therapeutic areas such as the central nervous system with ARO-MAPT for Alzheimer's disease and skeletal muscle with ARO-DM1 for type 1 myotonic dystrophy. These ventures are capital-intensive but hold the promise of addressing diseases with enormous unmet medical needs.

The funding also strengthens Arrowhead's position with its wholly-owned assets, complementing a portfolio of partnered programs with pharmaceutical giants like Novartis, Takeda, and GSK. This strategic balance allows the company to retain full value from its core assets while leveraging the resources and expertise of partners for others.

A Barometer of Biotech Investor Confidence

The market's enthusiastic reception of Arrowhead's offerings serves as a potent indicator of renewed investor confidence in high-science biotechnology. Leading up to the announcement, the company's stock (NASDAQ: ARWR) saw significant positive momentum, including a nearly 11% jump on January 6th.

Following the news, Wall Street analysts reinforced this optimism. Several firms, including Goldman Sachs and Morgan Stanley, raised their price targets on ARWR, citing the company's strengthened balance sheet and de-risked path toward commercializing its pipeline. The consensus rating among analysts remains a "Strong Buy," reflecting a belief that the company is poised for significant growth.

This successful, upsized raise comes after a period of volatility for the broader biotech sector. For a company to not only access the capital markets but to do so with such strong demand is a testament to its perceived quality and the potential of its RNAi technology. The transaction could be viewed as a bellwether, suggesting that investors are once again willing to write large checks for innovative companies with compelling clinical data and a clear strategic vision, even before they reach sustained profitability.

Arrowhead was already in a solid financial position, reporting $781.5 million in cash at the end of its 2025 fiscal year. This new infusion of capital extends its operational runway well into the future, providing the stability and resources needed to navigate the lengthy and expensive drug development process, prepare for multiple potential commercial launches, and negotiate future partnerships from a position of exceptional strength. The company now possesses the financial firepower to fully execute on its strategy of developing and commercializing a new class of medicines.